Align Financial’s Royalty Pharma RPRX Stock Holding History

Align Financial’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$467	Buy	+8	New	+$472	﹤0.01%	497

Other funds holding RPRX

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return

Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return

Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Inlet Private Wealth Jupiter, Florida $413M AUM 26.33% 1-Year Est. Return

Align Financial's RPRX Position: Q3 2026 in Review

Align Financial opened a new position in Royalty Pharma (RPRX) in Q3 2026: 8 shares worth $467. The stake represents ﹤0.01% of the portfolio and ranks #497 among its holdings.

95 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Align Financial held 8 shares of Royalty Pharma worth $467 as of Q3 2026.
Royalty Pharma was a new Align Financial position in Q3 2026.
Royalty Pharma made up ﹤0.01% of Align Financial's portfolio in Q3 2026, its #497 holding.
95 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Align Financial's 13F filing for Q3 2026, filed 16 Oct 2026.